BIS:NSD-ProShares UltraShort Nasdaq Biotechnology (USD)

ETF | Trading--Inverse Equity | NASDAQ Global Market

Last Closing

USD 20.24

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

3.60K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index?. The fund invests in derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times the inverse (-2x) of the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. It is non-diversified.

Inception Date: 06/04/2010

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.08%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Mer Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ 0.95 %

+0.14 (+2.02%)

USD 2.48B
ZBIO Zenas BioPharma, Inc. Common S.. 0.95 %

+0.41 (+1.99%)

N/A

ETFs Containing BIS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.01% 100% F 79% B-
Dividend Return 0.88% 50% F 49% F
Total Return 12.89% 100% F 80% B-
Trailing 12 Months  
Capital Gain 2.64% 100% F 56% F
Dividend Return 2.41% 50% F 37% F
Total Return 5.04% 100% F 56% F
Trailing 5 Years  
Capital Gain -72.36% 100% F 19% F
Dividend Return 1.84% 100% F 8% B-
Total Return -70.52% 100% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 14.14% 50% F 74% C
Dividend Return 14.45% 50% F 73% C
Total Return 0.31% 50% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 507.00% 100% F 4% F
Risk Adjusted Return 2.85% 50% F 43% F
Market Capitalization 0.07B 50% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.